Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Interest & Investment Income (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Interest & Investment Income for 5 consecutive years, with $700739.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 413.84% year-over-year to $700739.0, compared with a TTM value of $1.4 million through Dec 2025, up 11.36%, and an annual FY2025 reading of $1.4 million, up 11.36% over the prior year.
  • Interest & Investment Income was $700739.0 for Q4 2025 at SAB Biotherapeutics, up from $655233.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $700739.0 in Q4 2025 and bottomed at $3769.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $170175.4, with a median of $29248.5 recorded in 2022.
  • The sharpest move saw Interest & Investment Income skyrocketed 1829.64% in 2024, then plummeted 96.38% in 2025.
  • Year by year, Interest & Investment Income stood at $14871.0 in 2021, then skyrocketed by 101.26% to $29929.0 in 2022, then skyrocketed by 1517.31% to $484046.0 in 2023, then tumbled by 71.83% to $136374.0 in 2024, then surged by 413.84% to $700739.0 in 2025.
  • Business Quant data shows Interest & Investment Income for SABS at $700739.0 in Q4 2025, $655233.0 in Q3 2025, and $13562.0 in Q2 2025.